SCHEMBL22089482

SCHEMBL22089482

COc1cc2nccc(Oc3ccc(NC(=O)Cc4ccc(F)cc4F)cc3)c2cc1OC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 15/20 0.71
KDR P35968 15/20 0.71
MET P08581 4/20 0.66
KIT P10721 3/20 0.64
AXL P30530 2/20 0.64
RET P07949 2/20 0.64
DDR1 Q08345 2/20 0.64
AURKA O14965 1/20 0.64
RIPK2 O43353 1/20 0.64
ABCB11 O95342 1/20 0.64
ABL1 P00519 1/20 0.64
EGFR P00533 1/20 0.64
ERBB2 P04626 1/20 0.64
NTRK1 P04629 1/20 0.64
LCK P06239 1/20 0.64
PGR P06401 1/20 0.64
LYN P07948 1/20 0.64
CHRM2 P08172 1/20 0.64
HCK P08631 1/20 0.64
ADRA2A P08913 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371648 0.87 PDGFRA (0.84) PDGFRAKDRMETKITAXL
SCHEMBL1878918 0.87 KDR (0.83) PDGFRAKDRMETKITAXL
SCHEMBL22104149 0.85 PDGFRA (0.73) PDGFRAKDRMETKITAXL
SCHEMBL1880338 0.85 KDR (0.80) PDGFRAKDRMETKITAXL
SCHEMBL1875329 0.85 PDGFRA (0.72) PDGFRAKDRMETAXLFLT3
SCHEMBL22104179 0.85 PDGFRA (0.73) PDGFRAKDRMETKITAXL
SCHEMBL24142383 0.85 PDGFRA (0.79) PDGFRAKDRMETKITAXL
SCHEMBL5824367 0.85 PDGFRA (0.79) PDGFRAKDRMETKITAXL
SCHEMBL22104155 0.84 PDGFRA (0.74) PDGFRAKDRMETKITAXL
SCHEMBL1878889 0.84 PDGFRA (0.73) PDGFRAKDRMETKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404244-B2 Pan-KIT kinase inhibitor having quinoline structure and application thereof Tarapeutics Science Inc. (CN) 2025-09-02 US disclosed
US-20250186452-A1 NOVEL USE OF QUINOLINE COMPOUND Tarapeutics Science Inc. (CN) 2025-06-12 US disclosed
EP-4491181-A1 NOVEL USE OF QUINOLINE COMPOUND Tarapeutics Science Inc. (CN) 2025-01-15 EP disclosed
EP-3896059-B1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF TARAPEUTICS SCIENCE INC (CN) 2024-01-10 EP disclosed
CN-116763787-A New application of quinoline compound 安徽中科拓苒药物科学研究有限公司 2023-09-19 CN disclosed
WO-2023168740-A1 NOVEL USE OF QUINOLINE COMPOUND 安徽中科拓苒药物科学研究有限公司 2023-09-14 WO disclosed
WO-2023168740-A1 NOVEL USE OF QUINOLINE COMPOUND 安徽中科拓苒药物科学研究有限公司 2023-09-14 WO disclosed
CN-111303024-B Quinoline-structured pan-KIT kinase inhibitor and application thereof 安徽中科拓苒药物科学研究有限公司 2023-03-28 CN disclosed
US-20220064117-A1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF Tarapeutics Science Inc. (CN) 2022-03-03 US disclosed
US-20220064117-A1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF Tarapeutics Science Inc. (CN) 2022-03-03 US disclosed
EP-3896059-A1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF Tarapeutics Science Inc. (CN) 2021-10-20 EP disclosed
EP-3896059-A1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF Tarapeutics Science Inc. (CN) 2021-10-20 EP disclosed
CN-111303024-A Quinoline-structured pan-KIT kinase inhibitor and application thereof 安徽中科拓苒药物科学研究有限公司 2020-06-19 CN disclosed
WO-2020118753-A1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF 安徽中科拓苒药物科学研究有限公司 2020-06-18 WO disclosed
WO-2020118753-A1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF 安徽中科拓苒药物科学研究有限公司 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404244-B2 Pan-KIT kinase inhibitor having quinoline structure and application thereof KIT, MAP3K7, ABL1 PDGFRA 747/4885KDR 357/4885MET 1150/4885
US-20250186452-A1 NOVEL USE OF QUINOLINE COMPOUND ARG1, MSR1, SLC11A2 PDGFRA 2224/4885KDR 1464/4885MET 747/4885
US-20220064117-A1 PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF KIT, MAP3K7, ABL1 PDGFRA 747/4885KDR 357/4885MET 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.